EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Secreted Phosphoprotein 1 in Lung Diseases

Hongli Liu, Cristian Coarfa, Arzoo N Charania, Jennifer L Larson-Casey iD, Ivan O Rosas, Chao He iD

Metabolites · 30.05.2025 · 15 (6) · 365

DOI: 10.3390/metabo15060365 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 30.05.2025. Verfasst von Hongli Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35249, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIH HHS, National Institute of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Secreted phosphoprotein 1 (SPP1), also known as osteopontin (OPN) or early T lymphocyte activation protein 1 (ETA-1), is a multifunctional protein involved in numerous biological processes, including immune modulation, stress response, and tissue remodeling. The role of SPP1 in interstitial lung diseases (ILDs) has become an area of increasing interest, given its elevated expression in various ILDs such as idiopathic pulmonary fibrosis (IPF), connective tissue disease-associated ILD (CTD-ILD), and pneumoconiosis, especially with recent data derived from single-cell RNA sequencing. In addition to ILDs, SPP1 has been implicated in infectious granulomatous lung diseases, lung and pleural malignancies, airway diseases, and COVID-19. In most cases, higher SPP1 levels in serum, bronchoalveolar lavage fluid, or lung tissue carry a poor prognosis. SPP1 is expressed in multiple cells critical for fibrogenesis, including macrophages, epithelial cells, and fibroblasts, and SPP1 has emerged as a potential target for therapeutic interventions. Here, we review the proposed mechanisms by which SPP1 contributes to the development of lung disease, with an emphasis on ILD.

Schlagwörter

Stichwörter der Autor:innen

COPDSPP1asthmainterstitial lung diseaseslung cancerpulmonary fibrosis

Autor:innen und Institutionen

  • Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35249, USA.
  • Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
  • Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.

ORCID-Profile: Jennifer L Larson-Casey, Chao He

Förderung

  • NHLBI NIH HHS
  • NIH HHS
  • National Institute of Health

Zitieren

APA

Liu, H., Coarfa, C., Charania, A. N., Larson-Casey, J. L., Rosas, I. O., & He, C. (2025). Secreted Phosphoprotein 1 in Lung Diseases. Metabolites, 15(6), 365. https://doi.org/10.3390/metabo15060365

Vancouver

Liu H, Coarfa C, Charania AN, Larson-Casey JL, Rosas IO, He C. Secreted Phosphoprotein 1 in Lung Diseases. Metabolites. 2025;15(6):365. doi:10.3390/metabo15060365

BibTeX
@article{Liu2025,
  author = {Liu, Hongli and Coarfa, Cristian and Charania, Arzoo N and Larson-Casey, Jennifer L and Rosas, Ivan O and He, Chao},
  title = {Secreted Phosphoprotein 1 in Lung Diseases},
  journal = {Metabolites},
  year = {2025},
  volume = {15},
  number = {6},
  pages = {365},
  doi = {10.3390/metabo15060365}
}
Kostenlos starten →